ArticleObesity surgery2025
Treatment Pathways and Outcomes in Patients with BMI ≥ 50 kg/m
Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Analysis of the Supportive Care Needs after Metabolic Bariatric Surgery in Germany Using an Adjusted Supportive Care Needs Survey- Short Form (SCNS-SF34).Obesity surgery · 2026Article
- Letter to the Editor Regarding "Treatment Pathways and Outcomes in Patients with BMI ≥ 50 kg/mObesity surgery · 2025Article
- Comparative impact of different weight loss strategies on obstructive sleep apnea: an integrated review of surgical, pharmacological, and lifestyle interventions.Frontiers in neurology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBariatric surgery is the most effective treatment for patients with BMI ≥ 50 kg/m
methodsAll patients with BMI ≥ 50 kg/m
resultsOf 918 screened patients, 538 met inclusion criteria: Non-Surg (n = 203), Surg-First (n = 225), Step-Treat (n = 110). After 6 months, median % total weight loss (%TWL) and % excess weight loss (%EWL) were significantly higher in Surg-First (%TWL: 23.6% vs. 0%; %EWL: 42% vs. 0%; both P < .001) vs. Non-Surg. Surg-First showed higher diabetes remission (54.1% vs. 21.2%; P < .001) and fewer de novo diabetes cases. Compared to Surg-First, Step-Treat showed similar short-term weight loss but lower %TWL and %EWL at 12 and 24 months. Severe postoperative complications (Grade IIIb) were more common in Step-Treat (11.8% vs. 3.6%; P < .001), and SF-BARI QOL scores were higher in Surg-First.
conclusionIn patients with BMI ≥ 50 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.